Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 2/20 | 0.48 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GNRHR | P30968 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3054996 | 0.88 | AGTR1 (0.47) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL1886986 | 0.87 | LMNA (0.53) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL1891240 | 0.84 | LMNA (0.52) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL3831602 | 0.84 | LMNA (0.51) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL1892270 | 0.81 | LMNA (0.55) | POLBKDM4EGNRHRGAA | |
| SCHEMBL1886361 | 0.79 | PTGDR2 (0.58) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL3054998 | 0.79 | AGTR1 (0.47) | AGTR1AGTR2THRBRECQLL3MBTL1 | |
| SCHEMBL1889576 | 0.77 | AGTR1 (0.48) | AGTR1AGTR2THRBRECQLAPEX1 | |
| SCHEMBL1892701 | 0.77 | PTGDR2 (0.55) | POLBKDM4EGAA | |
| SCHEMBL1892914 | 0.76 | LMNA (0.49) | AGTR1AGTR2THRBRECQLGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH | 2011-05-05 | — | — | US | disclosed |
| US-7732618-B2 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH (US) | 2010-06-08 | — | — | US | disclosed |
| EP-1814865-A4 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | WYETH CORP (US) | 2009-09-02 | — | — | EP | disclosed |
| EP-1814865-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | Athersys, Inc. (US) | 2007-08-08 | — | — | EP | disclosed |
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | WYETH | 2006-05-18 | — | — | US | disclosed |
| WO-2006034418-A2 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | ATHERSYS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106081-A1 | Benzimidazole acetic acids exhibiting CRTH2 receptor antagonism and uses thereof | HRH2, TBXA2R, PTGDR2 | AGTR1 124/4885AGTR2 48/4885THRB 728/4885 |
| US-20110105573-A1 | BENZIMIDAZOLE ACETIC ACIDS EXHIBITING CRTH2 RECEPTOR ANTAGONISM AND USES THEREOF | HRH2, TBXA2R, PTGDR2 | AGTR1 124/4885AGTR2 48/4885THRB 728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.